Nanocarriers Mediated Topical Drug Delivery for Psoriasis Treatment

Background: Psoriasis is a chronic autoimmune inflammatory skin disease affecting 2 to 3% of people worldwide. Topical therapy as first option in the management of psoriasis is an attractive strategy by delivering drugs efficiently into target sites of disease, minimizing systemic side effects of drugs and ensuring high patient compliance. However, the delivery of antipsoriatic agents via conventional topical formulations is limited due to their poor percutaneous penetration and targeting into deeper layers of the skin. Keywords: Nanocarrier, psoriasis, skin delivery, skin targeting, topical delivery, anti-psoriatic drug.